Sinopharm discovers potent neutralising antibody against Delta variant
According to the researchers, the monoclonal antibody can effectively block the binding of novel coronavirus to the Angiotensin-converting enzyme
China-based Sinopharm announced that its research team has discovered a potent neutralising antibody against the Delta variant. The discovery could lead to short-term preventive and early treatment of COVID-19 triggered by this variant.
Yang Xiaoming, Chairman of Sinopharm China National Biotec Group, a Sinopharm subsidiary, with his team found a monoclonal antibody that can effectively block the binding of novel coronavirus to the Angiotensin-converting enzyme. According to the company, the enzyme is attached to the membrane of cells located in the intestines, kidney, testis, gallbladder, and heart and the antibody can prevent the virus from infecting cells.
The application of the antibody, called 2B11, can also significantly reduce the pulmonary inflammation caused by virus infection.
The company said the clinical application of the 2B11 antibody is progressing in an orderly manner with hopes that it can be used in the prevention and control of COVID-19 in China as soon as possible.
